Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

61 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Cytomegalovirus Infection With Retinitis After Brentuximab Vedotin Treatment for CD30+ Lymphoma.
Tudesq JJ, Vincent L, Lebrun J, Hicheri Y, Gabellier L, Busetto T, Merle C, Fegueux N, Ceballos P, Quittet P, Navarro R, Hillaire-Buys D, Cartron G. Tudesq JJ, et al. Among authors: quittet p. Open Forum Infect Dis. 2017 Apr 5;4(2):ofx091. doi: 10.1093/ofid/ofx091. eCollection 2017 Spring. Open Forum Infect Dis. 2017. PMID: 28638848 Free PMC article.
Clinical and Product Features Associated with Outcome of DLBCL Patients to CD19-Targeted CAR T-Cell Therapy.
Lamure S, Van Laethem F, De Verbizier D, Lozano C, Gehlkopf E, Tudesq JJ, Serrand C, Benzaoui M, Kanouni T, Quintard A, De Vos J, Tchernonog E, Platon L, Ayrignac X, Ceballos P, Sirvent A, François M, Guedon H, Quittet P, Mongellaz C, Conte A, Herbaux C, Bret C, Taylor N, Dardalhon V, Cartron G. Lamure S, et al. Among authors: quittet p. Cancers (Basel). 2021 Aug 25;13(17):4279. doi: 10.3390/cancers13174279. Cancers (Basel). 2021. PMID: 34503088 Free PMC article.
Low doses of GM-CSF (molgramostim) and G-CSF (filgrastim) after cyclophosphamide (4 g/m2) enhance the peripheral blood progenitor cell harvest: results of two randomized studies including 120 patients.
Quittet P, Ceballos P, Lopez E, Lu ZY, Latry P, Becht C, Legouffe E, Fegueux N, Exbrayat C, Pouessel D, Rouillé V, Daures JP, Klein B, Rossi JF. Quittet P, et al. Bone Marrow Transplant. 2006 Aug;38(4):275-84. doi: 10.1038/sj.bmt.1705441. Bone Marrow Transplant. 2006. PMID: 16883311 Free PMC article. Clinical Trial.
Optimizing the use of anti-interleukin-6 monoclonal antibody with dexamethasone and 140 mg/m2 of melphalan in multiple myeloma: results of a pilot study including biological aspects.
Rossi JF, Fegueux N, Lu ZY, Legouffe E, Exbrayat C, Bozonnat MC, Navarro R, Lopez E, Quittet P, Daures JP, Rouillé V, Kanouni T, Widjenes J, Klein B. Rossi JF, et al. Among authors: quittet p. Bone Marrow Transplant. 2005 Nov;36(9):771-9. doi: 10.1038/sj.bmt.1705138. Bone Marrow Transplant. 2005. PMID: 16113665 Free PMC article. Clinical Trial.
Reduced intensity conditioning: enhanced graft-versus-tumor effect following dose-reduced conditioning and allogeneic transplantation for refractory lymphoid malignancies after high-dose therapy.
Mohty M, Fegueux N, Exbrayat C, Lu ZY, Legouffe E, Quittet P, Lopez-Martinez E, Latry P, Avinens O, Hertog C, Klein B, Eliaou JF, Rossi JF. Mohty M, et al. Among authors: quittet p. Bone Marrow Transplant. 2001 Aug;28(4):335-9. doi: 10.1038/sj.bmt.1703134. Bone Marrow Transplant. 2001. PMID: 11571504
High response rate and acceptable toxicity of a combination of rituximab, vinorelbine, ifosfamide, mitoxantrone and prednisone for the treatment of diffuse large B-cell lymphoma in first relapse: results of the R-NIMP GOELAMS study.
Gyan E, Damotte D, Courby S, Sénécal D, Quittet P, Schmidt-Tanguy A, Banos A, Le Gouill S, Lamy T, Fontan J, Maisonneuve H, Alexis M, Dreyfus F, Tournilhac O, Laribi K, Solal-Céligny P, Arakelyan N, Cartron G, Gressin R; GOELAMS Group. Gyan E, et al. Among authors: quittet p. Br J Haematol. 2013 Jul;162(2):240-9. doi: 10.1111/bjh.12379. Epub 2013 May 21. Br J Haematol. 2013. PMID: 23692641 Free article. Clinical Trial.
61 results